GLP-1 RAs and Kidney Cancer Risk- Methodological Considerations in Active-Compara
A recent study using target trial emulation found no increased kidney cancer risk with GLP-1 RAs compared to SGLT2 inhibitors, challenging prior findings.
GLP-1 Receptor Agonists and NAION
GLP-1 receptor agonists likely increase NAION risk approximately twofold, but this rare event does not outweigh their cardiovascular and metabolic benefits for most patients.
GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain
GLP-1RAs show promise in reducing antipsychotic-induced weight gain without worsening psychiatric symptoms, offering a new approach for SPMI patients.
GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality
GLP-1 receptor agonists are associated with a statistically significant reduction in all-cause mortality for cancer patients with type 2 diabetes. This study highlights the potential benefits of GLP-1RAs in oncology settings.
GLP-1 therapies- an emerging approach for alcohol reduction?
A recent study found that semaglutide significantly reduced heavy drinking days and alcohol craving in adults with alcohol use disorder and obesity, offering a promising new approach.
GLP‑1 Receptor Agonist Treatment and Health Outcomes in Methadone‑Treated Patien
GLP-1 receptor agonists significantly reduced myocardial infarctions, opioid overdoses, and suicidal ideation in methadone-treated OUD patients with T2D.
GLP‑1 Receptor Agonist Use Across Preconception, Pregnancy, and the Postpartum P
GLP-1 RA use in pregnancy remains controversial due to limited human data. This review synthesizes available evidence on risks and benefits across reproductive stages.
Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Ca
Semaglutide 2.4 mg significantly lowers the risk of heart attacks, strokes, and mortality in ASCVD patients with overweight or obesity. This study highlights its broad benefits beyond diabetes management.
Modes of cannabis administration, cannabis and tobacco co-use, and associations
This study highlights that adults who co-use cannabis with tobacco are more likely to use combustible methods, leading to worse respiratory outcomes and higher cannabis consumption.
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and
Semaglutide treatment led to a 13.7 percentage point reduction in heavy drinking days compared to placebo in patients with alcohol use disorder and obesity.